Start in Taiwan, Expand Globally, Develop into an International Brand.
OBI operates with an excellent management team and efficient business model to create an international Taiwan brand, and to base in Taiwan and expand the horizon worldwide.
Courage to innovate
Change the future
Developing novel therapeutic agents for patients with unmet medical needs
What's New?
2025.Mar.18
News
New Chairman of OBIGEN Pharma: OBI Pharma CEO Heidi Wang Takes Over
Following the resignation of Mr. Frank Chen as Chairman, the board of directors of OBIGEN PHARMA unanimously elected Dr. Heidi Wang, CEO of its parent company, OBI Pharma, to assume the chairmanship of OBIGEN PHARMA today (18th). The position of corporate representative director, previously held by Mr. Frank Chen, has been taken up by Ms. […]
2025.Mar.12
News
OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award
Dr. Heidi Wang Accepts Award on Behalf of OBI Pharma at ADC Asia Congress 2025 and Gives a Presentation
At the ADC Asia Congress 2025 held today (3/12) in Singapore, OBI Pharma (4174.TWO) was honored with the “Most Promising ADC Clinical Candidate in Taiwan” award. This recognition follows OBI Pharma’s achievement last year as a candidate in the World ADC Awards, where it was shortlisted among the top eight international pharmaceutical companies. The award […]
2025.Feb.19
News
Invited to the 2025 Healthcare Conference in Taipei
Dr. Heidi Wang engaged in discussions on Regulatory Landscape and International Partnerships in Pharma and Diagnostics
The highly anticipated Healthcare Conference Taipei 2025 kicked off this Wednesday and Thursday (2/19-2/20). Dr. Heidi Wang, CEO of OBI Pharma (4174.TWO), was invited to participate in the panel discussion on ” Regulatory Landscape and International Partnerships in Pharma and Diagnostics” at the Regent Taipei on 2/19. Co-hosted by University of California, Berkeley School of […]
2024.Dec.31
News
OBI Pharma's OBI-992 Research Paper Featured on Cover and Selected as a First Disclosure Article in Molecular Cancer Therapeutics Journal
OBI Pharma (4174.TWO)’s independent work based on a TROP2-targeted Antibody-Drug Conjugate (ADC) anti-cancer asset, OBI-992, is published on the cover of the internationally renowned journal “Molecular Cancer Therapeutics” (MCT), with the article designated as a First Disclosure recommended publication. Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR), specializes in preclinical […]
2024.Dec.23
News
OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies Outreach in Japan and to Advance Glycan Production
Taipei, Taiwan. December 23, 2024 – OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADC) and active immunotherapies (4174. TWO), and GlyTech, Inc. (GlyTech), a Japan manufacturer that focuses on glycan production and chemical glycosylation technologies, have entered into a Marketing Agreement […]
2024.Dec.11
News
OBI Pharma Earns Sports Enterprise Certification Again
Building a Healthy Workplace and Fulfilling Sustainability Commitments
OBI Pharma (4174.TWO) has once again been awarded the Sports Enterprise Certification by the Ministry of Education. This afternoon (12/11), during the 2024 Sports Enterprise Certification Ceremony held by the Ministry’s Sports Administration, OBI Pharma and another international corporation were the only two biotech and pharmaceutical companies recognized. This achievement underscores OBI Pharma’s dedication to […]
2024.Dec.02
News
Key Technologies + Innovative Products + Flexible Business Models
Dr. Heidi Wang: Shaping OBI Pharma into a Leading and Thriving Global Biotech Company
OBI Pharma (4174.TWO) held an investor conference this afternoon (12/2), where CEO, Dr. Heidi Wang, unveiled the company’s five-year vision. Leveraging innovative ADC enabling technologies and key products, OBI Pharma has embraced new and flexible business models to work with local and global biotech firms and pharmaceutical companies. Through collaborations and licensing agreements, this strategy […]
2024.Nov.14
News
OBI Pharma Showcases Biomarker Innovations at Singapore APAC Summit
Precision Medicine Tools Drive Success in New Drug Development
Biomarkers have become indispensable indicators for precision oncology, providing crucial insights for evaluating drugs, assessing therapeutic activity, guiding patient selection in clinical trials, and determining potential future indications. OBI Pharma (4174.TWO) has been invited to deliver a keynote at the 2024 World Companion Diagnostics & Liquid Biopsy Summit APAC in Singapore on November 13-14. Dr. […]
2024.Sep.24
News
OBI-992 Shortlisted as the Most Promising Clinical Candidate in the 11th Annual World ADC Awards
OBI Pharma, Inc. (4174.TWO), a clinical-stage oncology company, announced that OBI-992, a TROP2 targeted antibody-drug conjugate (ADC), has been shortlisted from over 1,000 nominations submitted as one of the eight “2024 Most Promising Clinical Candidate” by the 11th Annual World ADC Awards. The World ADC Awards were created 11 years ago to commemorate scientific excellence […]
2024.Aug.22
News
The 2nd World ADC Linker & Conjugation Summit – OBI Pharma Presents Results on Patented Enzyme - EndoSymeOBI® - for ADCs
OBI Pharma (4174.TWO) presented the results of its patented enzyme, EndoSz, used to power the exclusive glycan-based ADC platform GlycOBI®, at the 2nd World ADC Linker & Conjugation Summit held in Boston, Massachusetts August 20-22, 2024. EndoSz is an enzyme derived from Streptococcus equi subsp. zooepidemicus Sz105, also known as endo-β-N-acetylglucosaminidase. OBI Pharma has obtained […]
2024.Aug.07
News
OBI-992 has been approved by US FDA for Orphan Drug Designation for the treatment of gastric cancer
OBI Pharma, a clinical-stage oncology company (4174.TWO), received the notification letter today from US FDA, stating that the request for Orphan Drug Designation of OBI-992 TROP2 ADC for the treatment of gastric cancer, including gastroesophageal junction cancer, has been approved. Heidi Wang, Ph.D, OBI Pharma’s Chief Executive Officer pointed out, the U.S. FDA grants Orphan […]
2024.Jun.26
News
OBI 's Proprietary Enzyme EndoSymeOBI™ Featured on Cover of Prestigious International Journal, JACS Au.
OBI Pharma’s proprietary enzyme, EndoSymeOBI™, recently being featured on the cover of the JACS Au. This recognition underscores the promising potential of the enzyme in the field of new drug development. OBI Pharma’s proprietary enzyme, EndoSymeOBI™, recently being featured on the cover of the JACS Au. This recognition underscores the promising potential of the enzyme […]
2024.Jun.21
News
Dr. Heidi Wang, CEO of OBI Pharma, Inc., Selected as One of the Top 10 Managers of High-performing Enterprises by the Golden Torch Award
Taipei, Taiwan – The Golden Torch Award, a prestigious program that honors outstanding corporate leaders, announced today (June 21) that Dr. Heidi Wang, CEO of OBI Pharma, Inc. (4174.two), has been selected as one of the “Top 10 Managers of High-performing Enterprises”. Dr. Wang holds a Ph.D. in Molecular Biology and Virology from the University […]
2024.Jun.28
News
OBI Pharma shareholders’ meeting launches new company strategy and embraces transformation
Strong emphasis on developing ADC assets and technology platform and encouraging global collaborations and partnership OBI PHARMA, INC. (4174 TWO ) has undergone meaningful transformation over the past year. From pipeline refresh, organizational restructuring, to cultural revitalization, the company’s commitment to innovation is evident. Dr. Heidi Wang, CEO of OBI, emphasizes that this transformation […]
2024.Jun.12
News
OBI Pharma announces Phase 1/2 study initiation for OBI-992, a TROP2-targeted antibody drug-Conjugate (ADC) for cancer therapy
Clinical trial to evaluate the safety and efficacy of OBI-992 in advanced solid tumors. TAIPEI, Taiwan, June 12, 2024, ─ OBI Pharma, a clinical-stage oncology company (4174.TWO), today announced the initiation of a Phase 1/2 clinical trial of OBI-992, an antibody-drug conjugate (ADC) targeting TROP2 (Trophoblast cell-surface antigen 2), an antigen overexpressed in multiple tumor […]
2024.Dec.31
News
OBI Pharma's OBI-992 Research Paper Featured on Cover and Selected as a First Disclosure Article in Molecular Cancer Therapeutics Journal
2024.Dec.02
News
Key Technologies + Innovative Products + Flexible Business Models
Dr. Heidi Wang: Shaping OBI Pharma into a Leading and Thriving Global Biotech Company
2024.Aug.22
News
The 2nd World ADC Linker & Conjugation Summit – OBI Pharma Presents Results on Patented Enzyme - EndoSymeOBI® - for ADCs
Who We Are